Nature Immunology：康毅滨团队发现提高树突状细胞疫苗抗癌效果的新靶点

Core Viewpoint - Dendritic cell vaccines have potential in cancer immunotherapy, but their success has been limited due to unidentified mechanisms of induced tolerance [2][3]. Group 1: Research Findings - A study published by Professor Kang Yibin's team at Princeton University identified that dendritic cells express ALDH1A2 and secrete retinoic acid (RA), which inhibits dendritic cell activity [3][6]. - The research developed a small molecule inhibitor, KyA33, that effectively targets ALDH1A2, reducing RA production and enhancing the efficacy of antitumor dendritic cell vaccines [3][6]. - The study demonstrated the unique role of the ALDH1A2-RA signaling axis in regulating dendritic cell function and proposed KyA33 as a potential drug for cancer immunotherapy [6].